|June 4, 2014|
|18:47 EDT||NVAX, HALO, VRNT, PVH, RLD, TSL, AXAS, FIVE||On The Fly: After Hours Movers |
UP AFTER EARNINGS: Verint Systems (VRNT), up 6.78% after reporting better than expected first quarter results and raising fiscal 2015 guidance... Five Below (FIVE), up 2.87% after reporting quarterly results... RealD (RLD), up 1.7%. ALSO HIGHER: Halozyme Therapeutics (HALO), up 13.24% after the FDA removed the clinical hold on patient enrollment and dosing of PEGPH20 in the ongoing Phase 2 trial... Abraxas Petroleum (AXAS), up 6.67% after raising its fiscal 2014 production guidance to 5,500-5,700 Boepd. DOWN AFTER EARNINGS: PVH Corp. (PVH), down 6.26% after lowering fiscal 2014 guidance... ALSO LOWER: Novavax (NVAX), down 8.66% after filing to sell $100M of common stock... Trina Solar (TSL), down 3.79%.
News For VRNT;FIVE;RLD;HALO;AXAS;PVH;NVAX;TSL From The Last 14 Days
|July 2, 2015|
|07:26 EDT||RLD||B. Riley recommends adding to IMAX and RealD positions|
B. Riley recommends adding to IMAX (IMAX) and RealD (RLD) positions given improving underlying box office market share trends, increasing exposure to international box office markets, and company specific catalysts.
|July 1, 2015|
|07:30 EDT||TSL||Drop is Solar stocks a buying opportunity, says Deutsche Bank|
Deutsche Bank analyst Vishal Shah attributes the recent weakness in the Solar space to investor concerns around increased interest rate and growth uncertainty, especially of YieldCos. Shah, however, views YieldCos as a significant growth catalyst for the solar and broader renewables sector. The analyst expects the current weakness to provide an attractive entry point for longer term investors. Publicly traded companies in the space include Canadian Solar (CSIQ), First Solar (FSLR), JA Solar (JASO), SunPower (SPWR), Trina Solar (TSL) and Yingli Green Energy (YGE).
|June 30, 2015|
|06:39 EDT||RLD||RealD sell-off a buying opportunity, says B. Riley|
Subscribe for More Information
|June 25, 2015|
|07:27 EDT||PVH||PVH Corp. remains top softlines pick, says UBS|
UBS said PVH Corp. remains its top softlines pick, citing improving Q2 trends, confidence that the company will report a beat and raise quarter and multiple sources of earnings upside and multiple expansion that will drive stock performance. UBS reiterated its Buy rating and $132 price target on PVH Corp.
|June 23, 2015|
|10:00 EDT||FIVE||On The Fly: Analyst Initiation Summary|
Today's noteworthy initiations include: Adeptus Health (ADPT) initiated with a Buy at BofA/Merrill... Angie's List (ANGI) initiated with a Hold at Topeka... Avenue Financial (AVNU) initiated with an Equal Weight at Stephens... CASI Pharmaceuticals (CASI) initiated with a Buy at H.C. Wainwright... Corindus (CVRS) initiated with a Buy at Stifel... Coupons.com (COUP) initiated with a Market Perform at William Blair... Five Below (FIVE) initiated with an Outperform at RBC Capital... Franklin Financial Network (FSB) initiated with an Equal Weight at Stephens... Galmed (GLMD) initiated with a Buy at H.C. Wainwright... Genesis Healthcare (GEN) initiated with a Neutral at Susquehanna... Groupon (GRPN) initiated with a Hold at Topeka... GrubHub (GRUB) initiated with a Buy at Topeka... Hercules Technology (HTGC) initiated with a Buy at Compass Point... Immersion (IMMR) initiated with a Buy at Craig-Hallum... Lipocine (LPCN) initiated with a Buy at Canaccord... NeoGenomics (NEO) initiated with a Buy at BTIG... Novadaq (NVDQ) initiated with a Neutral at BTIG... Perrigo (PRGO) initiated with an Outperform at BMO Capital... Signal Genetics (SGNL) initiated with a Buy at Chardan... Standard Motor Products (SMP) initiated with a Neutral at CL King... United Community Financial (UCFC) initiated with a Market Perform at Keefe Bruyette... WP Glimcher (WPG) initiated with a Neutral at Goldman... WhiteWave (WWAV) initiated with a Buy at Maxim... Yelp (YELP) initiated with a Buy at Topeka.
|07:16 EDT||FIVE||Five Below initiated with an Outperform at RBC Capital|
|June 22, 2015|
|07:45 EDT||HALO||Halozyme price target raised to $25 from $20 at JPMorgan|
JPMorgan raised its price target for Halozyme to $25 after speaking with CEO Hellen Torley. The firm remains positive on the potential for PEGPH20 and keeps an Overweight rating on the stock.